Group 1 - The company has undergone significant integration since the merger of Mylan and Upjohn, focusing on streamlining operations and divesting non-core assets [4][5] - The strategic direction for the next 3 to 5 years emphasizes moving up the value chain towards more durable high-growth brands [3] - Recent divestments include biosimilars, OTC products, women's health, and active pharmaceutical ingredients (API) [4] Group 2 - The company is committed to executing its strategy by leveraging a diverse base of business assets [5]